To evaluate the role of TNF-␣ in the pathogenesis of hyperandrogenism, we have evaluated the serum TNF-␣ levels, as well as several polymorphisms in the promoter region of the TNF-␣ gene, in a group of 60 hyperandrogenic patients and 27 healthy controls matched for body mass index.
H YPERANDROGENISM, OR ANDROGEN excess, is
possibly the most frequent endocrine disorder in women of reproductive age. Hirsutism is a clinical manifestation of androgen excess and is present in 7.1% of Spanish women in this age range (1) . The most common cause of hirsutism is polycystic ovary syndrome (PCOS), as defined by endocrine criteria (2) , showing a 6.5% prevalence in Spanish women (1) .
The increasing evidence that hyperandrogenism and PCOS have a genetic basis (3, 4) has stimulated research into the genes involved in the pathogenesis of these disorders. Despite significant efforts, the precise genetic mechanisms leading to hyperandrogenism remain unknown, suggesting that this disorder is a complex trait in terms of inheritance.
TNF-␣ influences the reproductive axis, inducing changes that closely resemble those found in patients with PCOS and hyperandrogenism. TNF␣ stimulates proliferation and steroidogenesis in rat theca cells in vitro (5, 6) , facilitating the effects of insulin and IGF-I in a dose-dependent and additive fashion (6) . Moreover, TNF␣ may be involved in apoptosis and anovulation in the rat ovary (7) . In humans, increased serum TNF␣ levels have been found in lean PCOS patients (8) , but no differences in the follicular TNF␣ content have been found between normal and polycystic ovaries (9) .
TNF␣ has several metabolic activities. Hyperexpression of TNF-␣ in adipose and muscle tissue has been proposed to play a key role in the development of insulin resistance in humans (10, 11) by decreasing the tyrosine kinase activity of the insulin receptor (12) . This effect is mediated by the insulin-receptor substrate-1 (12) , is associated with an increased expression of TNF␣ receptors in adipose tissue (13, 14) , and can be antagonized by troglitazone in experimental animals (15) . Although TNF␣ acts through autocrine-paracrine mechanisms in adipose and muscle tissue, increased serum levels of TNF-␣ have been found in several conditions associated with insulin resistance, such as type 2 diabetes mellitus (16) and obesity (17) . TNF␣ is also a significant source of genetic variability. There are several single nucleotide polymorphisms in the regulatory region of the TNF␣ gene, and some of them have been proposed to play a role in the pathogenesis of insulin resistance, type 2 diabetes mellitus, and obesity (18 -20) , among other disorders.
Hyperandrogenism, including PCOS and hirsutism with normal ovulation, is present in as many as 50% of women diagnosed with type 2 diabetes mellitus (21) ; conversely, impaired glucose tolerance is a frequent finding in PCOS and non-PCOS hyperandrogenic patients (22, 23) . The association of obesity with hyperandrogenism is also well known (24) . Therefore, the genes related to type 2 diabetes mellitus and obesity are considered candidate genes for the inheritance of hyperandrogenism (25) .
The present study was undertaken to further delimitate the influence of TNF␣ on the pathogenesis of female hyperandrogenism, using a clinical, biochemical, and molecular genetic approach.
Materials and Methods Subjects
Sixty consecutive hyperandrogenic patients, aged 24.3 Ϯ (sd) 6.6 yr with a body mass index (BMI) 29.0 Ϯ (sd) 8.4 kg/m 2 , were studied. Hirsutism, as defined by the presence of excessive body hair distributed in an androgen-dependent pattern, with a modified Ferriman-Gallwey score (26) of 8 or more, was present in 57 of the patients with a score of 14.6 Ϯ (sd) 5.3.
Menstrual cycle intervals were evaluated on recall for every patient. Oligomenorrhea was defined by the presence of 6 or more cycles of more than 36 days in the previous year, and amenorrhea by lack of vaginal bleeding for 3 consecutive months (27) . Oligomenorrhea and amenorrhea were considered as indicative of ovulatory dysfunction, but no further effort was made to demonstrate oligo-ovulation. Oligomenorrhea or amenorrhea were present in 21 of the 60 patients, including 18 of the 57 hirsute patients and 3 women who did not have hirsutism (their hirsutism scores were 6, 7, and 7) but presented with oligomenorrhea and increased serum total T levels.
The reference values for the analytical procedures were obtained from a control group of 27 normal menstruating women, aged 30.2 Ϯ (sd) 8.7 yr, matched for BMI (28.9 Ϯ (sd) 7.7 kg/m 2 ), who did not have signs and symptoms of hyperandrogenism or family history of endocrine diseases.
None of the patients had hypertension, features of Cushing's disease, or drug-induced hirsutism. Hyperprolactinemia and congenital adrenal hyperplasia were ruled out because all the patients presented basal serum PRL levels Ͻ24 g/liter, together with ACTH-stimulated 17-hydroxyprogesterone (17-OHP) levels Ͻ30 nmol/liter and ACTH-stimulated 11-deoxycortisol levels (S) Ͻ26 nmol/liter (which is the mean ϩ 2 sd of the values obtained from the control group).
Data from some patients and controls, regarding different aspects of the pathophysiology of hirsutism, have been previously published (28) . The patients and controls had not taken hormonal medications, including contraceptive pills, for the last 6 months. All the patients and controls were Caucasian. The ethics committee of the Hospital Ramó n y Cajal approved the study, and informed consent was obtained from each patient and control.
Study protocol, hormone profiles, and diagnostic categories of hyperandrogenism
Studies were performed between days 5 and 10 of the menstrual cycle or during amenorrhea, after excluding pregnancy by proper testing. The patients reported to the Endocrine-Metabolic testing room between 0800 and 0900 h after a 12-h overnight fast. An indwelling iv line was placed in a forearm vein, and after 15-30 min, basal blood samples were obtained for the measurement of TNF␣, total T, ⌬ 4 -androstenedione (⌬ 4 -A), 17-OHP, dehydroepiandrosterone-sulfate (DHEAS), cortisol (F), LH, FSH, E2, SHBG, glucose, and insulin. Immediately after taking basal samples, a 250-g iv bolus of 1-24 ACTH (Synacthen, Ciba-Geigy, Basel, Switzerland) was injected and blood samples were obtained at 0 and 60 min for the measurement of S, 17-OHP, and ⌬ 4 -A. Finally, in all the patients and 19 controls, a 10-g/kg body weight sc dose of leuprolide was injected (29) , and samples were obtained at 0900 h on the next day for measurement of LH, FSH, E2, F, T, SHBG, 17-OHP, and ⌬ 4 -A. Serum LH, FSH, and E2 served to confirm the stimulatory effect of leuprolide on gonadotropin and ovarian steroid secretion, and F levels were measured in all the subjects to rule out an interference of the stimulatory effect of the ACTH test performed the day before, on serum 17-OHP and ⌬ 4 -A levels. Samples were immediately centrifuged and serum was separated and frozen at Ϫ20 C until assayed.
Serum TNF␣ levels were measured within a single assay by solidphase, two-site chemiluminescent enzyme immunometric technique (Immulite, Diagnostic Products Corp., Los Angeles, CA) with a sensitivity of 1.7 pg/ml and a mean intra-assay coefficient of variation of 3.2%. The technical characteristics of the assays employed for hormone measurements have been reported previously (30, 31) . The free testosterone (FT) concentration was calculated from T and SHBG concentrations, assuming a serum albumin concentration of 43 g/liter, and taking a value of 1 ϫ 10 9 liter/mol for the association constant of SHBG for T and a value of 3.6 ϫ 10 4 liter/mol for that of albumin for T (32) . Insulin resistance was estimated from fasting glucose and insulin levels using the homeostatic model assessment (HOMAIR) (33) and using the quantitative insulin sensitivity check index (QUICKI) (34) .
Patients were classified clinically as follows: Women presenting with hirsutism or hyperandrogenemia and menstrual dysfunction (n ϭ 21) were diagnosed with PCOS according to the criteria derived from the National Institute for Child Health and Human Development 1990s conference (2) . Hirsute patients with increased circulating concentrations of T, FT, DHEAS, and/or ⌬ 4 -A and regular menstrual cycles were considered to have hyperandrogenemic hirsutism (n ϭ 28). Hirsute patients with normal serum T, FT, DHEAS, and ⌬ 4 -A levels and regular menstrual cycles were diagnosed with idiopathic hirsutism (n ϭ 11). Independently, the presence or absence of functional ovarian hyperandrogenism (FOH), as defined by increased 17-OHP levels after leuprolide administration, was also considered.
The 95th percentile upper limits of normality for basal serum androgens, derived from the control group of 27 healthy women, were 2.15 nmol/liter, 35 pmol/liter, 9.5 mol/liter, and 15.7 nmol/liter for T, FT, DHEAS, and ⌬ 4 -A, respectively. The 95th percentile upper limit of normality for the leuprolide test, derived from 19 women in the control group, was a serum 17-OHP level of 7.6 nmol/liter.
DNA extraction and genotype analysis
Genomic DNA was extracted from leukocytes obtained from whole blood samples, using commercial DNA purification kits (Wizard Genomic DNA purification kit, Promega Corp., Madison, WI, and Nucleon BAC C3, Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom). PCR primers were designed to amplify 2 fragments of the promoter of TNF␣ gene. The first fragment, spanning from Ϫ1232 to Ϫ732 relative to the TNF␣ gene transcription start site, comprises a DNA region that contains the Ϫ1196C/T, Ϫ1125G/C, Ϫ1031T/C, Ϫ863C/A, and Ϫ857C/T polymorphisms described previously (35) . Primer sequences were 5Ј-TCT GCT TGT GTG TGT GTG TCT G-3Ј (sense) and 5Ј-ATG AAG CTC TCA CTT CTC AGG G-3Ј (antisense). A second fragment, spanning from Ϫ444 to Ϫ88 and containing the Ϫ316G/A, Ϫ308G/A, Ϫ238G/A, and Ϫ163G/A polymorphisms (36), was also amplified. Primer sequences were 5Ј-CAA CGG ACT CAG CTT TCT GAA G-3Ј (sense) and 5Ј-TGG AGA AAC CCA TGA GCT CAT C-3Ј (antisense).
DNA sequences were amplified in an automated thermocycler (GeneAmp PCR System 2400, PE Applied Biosystems, Foster City, CA), using a 25-l reaction mix containing 1 U of AmpliTaq polymerase (PE Applied Biosystems). PCR conditions for both fragments included an initial denaturating step at 94 C for 1 min, 30 cycles at 94 C for 1 min, at 60 C for 1 min, and at 72 C for 1 min, and a final extension at 72 C for 10 min.
After PCR amplification, alleles for each polymorphism were identified by direct sequence as follows. PCR products were purified using QIAquick purification kit (QIAGEN GmbH, Hilden, Germany). Sequence analysis was carried out using the dRhodamine Terminator Cycle DNA Sequencing Ready Reaction Kit (PE Biosystems, Warrinton, UK) using the antisense primer for the first fragment of the TNF␣ gene promoter and the sense primer for the second fragment. The cyclesequencing products were precipitated and analyzed by an ABI 310 automated sequencer (PE Applied Biosystems) according to the manufacturer's instructions.
Statistical analysis
Results are expressed as mean [median] Ϯ sd in the text and tables, unless otherwise stated. The Kolmogorov-Smirnov statistic, with a Lilliefors significance level for testing normality, was applied to continuous variables. Because most of the variables did not follow a normal distribution, nonparametric tests were applied. The Mann-Whitney UWilcoxon rank sum W test or the Kruskall-Wallis test were used to compare variables among the groups of subjects, as appropriate. For variables showing significant differences between the groups by the Kruskall-Wallis test, repeated Mann-Whitney U -Wilcoxon rank sum W tests were used to identify the differences between each pair of groups, applying an a priori downward correction to the level of significance to compensate for multiple comparisons (i.e. P Ͻ 0.0125 is needed to reach statistically significant differences when comparisons involve four groups) (37) . A 2 test was used for discontinuous variables, and Spear-man's nonparametric correlation analysis was also used. P Ͻ 0.05 was considered statistically significant, with the exception stated above. Power analysis was performed using the G•Power software (38) . Because power analysis requires parametric tests instead of the nonparametric tests used here, sample sizes for 0.80 statistical power were calculated for the equivalent parametric tests (i.e., t test or one-way ANOVA), and the results were corrected for the asymptotic relative efficiency of the nonparametric tests relative to their parametric equivalents (39) .
Results

Serum TNF␣ levels and hormone profiles
When considered as a whole, the group of 60 hyperandrogenic patients presented with mildly increased serum TNF␣ levels as compared with the healthy controls, although there was a considerable overlap among these groups (Fig. 1) .
Patients presented increased serum T, FT, basal and ACTH-stimulated ⌬ 4 -A and 17-OHP, and DHEAS concentrations, and decreased SHBG levels, as compared with controls ( Table 1) . No differences were observed in basal LH, FSH, E2, and insulin resistance as measured by HOMAIR and QUICKI indexes (Table 1) . Serum TNF␣ levels showed weak but statistically significant correlations, with basal and ACTH-stimulated serum ⌬ 4 -A concentrations (r ϭ 0.286, P Ͻ 0.01; and r ϭ 0.222, P Ͻ 0.05, respectively), when considering patients and controls as a whole. No other statistically significant correlations were observed (data not shown).
When considering the clinical diagnostic categories of hyperandrogenism, the differences in serum TNF␣ levels among controls and patients with PCOS (n ϭ 21), hyperandrogenemic hirsutism (n ϭ 28), and idiopathic hirsutism (n ϭ 11) did not reach statistical significance (controls, 5.6[4.4] Ϯ 4.0 pg/ml; PCOS, 7.3[6.7] Ϯ 3.7 pg/ml; hyperandrogenemic hirsutism 6.8 [7. 0] Ϯ 2.7 pg/ml; and idiopathic hirsutism, 8.1 [7. 6] Ϯ 4.1 pg/ml; P ϭ 0.099). However, the statistical power was not enough to rule out such a difference (a total sample size of 209 subjects is needed for 0.80 power).
Fourteen patients (8 from the PCOS group and 6 from the group with hyperandrogenic hirsutism) were diagnosed with FOH (40) 
Single nucleotide polymorphisms in the TNF␣ gene
None of the polymorphisms in the promoter of the TNF␣ gene studied here was associated with patient or control status (Table 2) , with the diagnostic category of hyperandrogenism (data not shown) or with the presence or absence of FOH (data not shown).
The frequencies of these polymorphisms in hyperandrogenic patients and healthy controls are summarized in Table  2 . However, because of the limited sample size, our study does not have enough statistical power to detect true but small differences in the proportions of affected and nonaffected individuals among patients and controls (Table 2) . Nevertheless, none of the subjects presented the Ϫ163A and the Ϫ1196T variants, and only one patient presented the Ϫ1125C variant.
We then studied the influence of these polymorphisms on the serum TNF␣ levels and on the hormonal profiles. When considering hyperandrogenic patients and controls as a whole, carriers of the Ϫ308A variant presented with increased basal FT, 17-OHP, ⌬ 4 -A, and DHEAS levels and increased serum T, FT, 17-OHP, and ⌬ 4 -A levels after leuprolide administration, compared with subjects with wildtype (Ϫ308G) alleles (Table 3) . No differences were observed in serum TNF␣, basal T, ACTH-stimulated 17-OHP, and ⌬ 4 -A and basal and leuprolide-stimulated LH, FSH, and E2 levels or in insulin resistance as measured by HOMAIR and QUICKI indexes (Table 3 ). All these parameters showed no statistically significant differences when studying patients and controls separately.
Also, no differences were observed in serum determinations among individuals with wild-type alleles, compared with subjects hetero-or homozygous for the Ϫ238A, Ϫ316A, Ϫ857T, Ϫ863A, and Ϫ1031C variants (data not shown).
Influence of obesity in serum TNF␣ levels and association with TNF␣ gene polymorphisms
As stated above, the BMI was used to match patients and controls, explaining why the study groups showed no statistically significant differences for this variable. For comparisons between lean and obese subjects (obesity was defined by a BMI Ն 25 kg/m 2 ), patients and controls were studied as a whole. Obese subjects presented higher serum TNF␣ concentrations (7.4 These results persisted when studying patients alone, but when the analysis was restricted to healthy controls, only the differences in HOMAIR and QUICKI remained statistically significant (data not shown).
We then compared serum TNF␣ levels between patients and controls in obese and in lean subjects separately. Serum TNF␣ levels were higher in the 23 lean patients, compared with the 10 lean controls (6. Finally, none of the polymorphisms in the promoter of the TNF␣ gene were associated with obesity (data not shown).
Discussion
The possible involvement of TNF␣ in the pathogenesis of hyperandrogenism is based on several recent findings. TNF␣ might be related to increased ovarian steroid secretion, anovulation, and ovarian apoptosis in animals (5-7), features that resemble those of hyperandrogenism in humans.
Also, as reviewed by Hotamisligil (41) , virtually all animal and human models of obesity and insulin resistance are associated with TNF␣ messenger RNA and protein hyperexpression. As stated above, obesity and insulin resistance are frequent findings in hyperandrogenic women (42) . No statistically significant associations were observed when considering hetero-and homozygous subjects separately. a One patient was homozygous for this variant. b Two controls were homozygous for this variant. c Three patients were homozygous for this variant. d Three controls were homozygous for this variant. e Five patients were homozygous for this variant.
Our present results suggest that TNF␣ might play a role in the etiology of hyperandrogenism. Serum TNF␣ levels were increased, although with significant overlap, in patients, compared with healthy controls. Because both groups were matched for BMI, this increase is apparently independent of obesity. Moreover, in our series the indexes of insulin resistance were similar in patients and controls. Therefore, the mildly increased serum TNF␣ levels found in our hyperandrogenic patients appear to be also independent of insulin resistance.
Obesity alone modulates serum TNF␣ levels, which, as has been described by others (16, 17) , were higher in obese subjects, compared with lean individuals. Obese subjects also presented a higher degree of insulin resistance, lower SHBG, and increased FT, compared with lean subjects. When subjects were classified by body weight, serum TNF␣ levels were increased only in lean patients, compared with lean controls, but this difference was not maintained when comparing obese patients with obese controls. Gonzalez et al. (8) recently reported similar results in PCOS patients.
Therefore, our present results confirm that serum TNF␣ levels increase mainly because of obesity both in controls and hyperandrogenic women but also point to a different mechanism in relation to hyperandrogenism. Interestingly, the higher serum TNF␣ levels were found in the less severe hyperandrogenic women according to the leuprolide test, and serum TNF␣ levels tended to be higher in women with idiopathic hirsutism.
Whether these tendencies reflect a pathogenic mechanism cannot be solved by our present results but, because TNF␣ acts mostly if not completely by autocrine or paracrine mechanisms (43) , it is also possible that the fluctuations in serum TNF␣ levels may have no pathogenic significance, representing only secondary events not actually related to the development of hyperandrogenism.
Nevertheless, in our series the TNF␣ system also influenced hyperandrogenism from a genetic perspective. Although none of the polymorphisms studied here was more frequent in hyperandrogenic patients, the Ϫ308A variant in the promoter of the TNF␣ gene clearly influenced the phenotype, resulting in increased basal and leuprolide-stimulated androgen concentrations in the group of carriers of this variant.
The Ϫ308G/A polymorphism in the promoter of the TNF␣ gene has been studied extensively. The Ϫ308A variant, which is associated with human leukocyte antigens A1, B8, and DR3 alleles (44) , is a much more powerful transcription activator, compared with the Ϫ308G allele (45, 46) , explaining the increased TNF␣ production found in these individuals (47) .
Based on these previous studies, we hypothesize that carriers of the Ϫ308A allele might have increased TNF␣ production in several tissues, including the ovary. In such a case, the increased TNF␣ levels may stimulate ovarian ⌬ 4 -A secretion in theca cells as occurs in experimental animals (5). However, definite proof would require in vitro studies that are far beyond the methodology of our present study.
Because the increased androgen secretion in Ϫ308A carriers was observed when considering patients and controls as a whole, the Ϫ308A variant in the promoter of the TNF␣ b Although no statistically significant differences in BMI, HOMAIR, and QUICKI were observed, analysis of covariance was performed to rule out a possible influence of these variables on the differences found in serum hormone levels. Normality was ensured by logarithmic transformation before analysis of covariance. After controlling for BMI, HOMAIR, and QUICKI, leuprolide-stimulated T, basal and leuprolidestimulated FT, basal 17-OHP, and basal and leuprolide-stimulated ⌬ 4 -A serum concentrations remained significantly increased in carriers of the Ϫ308A variant as compared with subjects homozygous for the Ϫ308G allele.
gene should be considered only as a contributing factor to the development of hyperandrogenism instead of the main etiologic factor for this condition. Interestingly, serum TNF␣ levels were similar in Ϫ308A carriers and in subjects presenting wild-type alleles, pointing to a local effect of TNF␣ on androgen secreting tissue rather than to an endocrine effect mediated by circulating TNF␣.
On the contrary, neither the Ϫ308G/A polymorphism nor any of the other TNF␣ gene polymorphisms studied here were associated with patient or control status. Milner et al. (48) recently reported similar results, failing to demonstrate an association of the Ϫ308G/A polymorphism with PCOS in their series. However, Milner et al. (48) did not observe differences in serum androgens depending on the Ϫ308G/A polymorphism, but they measured only T and ⌬ 4 -A. The association of variants in the promoter of the TNF␣ gene with obesity and insulin resistance is controversial, and there have been negative (36, 49 -52) and positive (18 -20) reports for these associations over the last years. In our series, none of the polymorphisms in the promoter of the TNF␣ gene were associated with obesity, and these polymorphisms did not influence serum TNF␣ levels, BMI, HOMAIR, or QUICKI, which were not different among the carriers of these variants and subjects presenting wild-type alleles. Albeit we have assessed insulin resistance by relatively insensitive methods, our present results cannot demonstrate any association between obesity and insulin resistance with the polymorphisms in the promoter of the TNF␣ gene studied here.
Sample size and statistical power merits an explanation. Statistical power, as the complement of type II error, reflects the ability of a study to detect a true difference (37) . Therefore, low power indicates an elevated probability of concluding erroneously that there are no differences or associations in a study. As a rule, a 0.80 power is considered adequate (37) . Our present study lacks enough power to accurately rule out that the proportions of affected and nonaffected individuals for the polymorphisms in the TNF␣ gene were actually different among hyperandrogenic patients and controls.
Yet even in the case that these differences actually exist, they are too small (the higher was a 10-point difference in the percentage of affected individuals among patients and controls) to represent a major mechanism in the pathogenesis of hyperandrogenism. Moreover, as stated above, the study by Milner et al. (48) ruled out an association of the Ϫ308A variant with PCOS, and the sample size in this study provided adequate statistical power.
In conclusion, our present results suggest that the TNF␣ system might play a role in the pathogenesis of hyperandrogenism, independent of obesity and insulin resistance. Not only serum TNF␣ levels were increased in patients, compared with controls, but also the Ϫ308G/A polymorphism in the promoter of the TNF␣ gene modulated ovarian function, resulting in increased serum androgen levels in carriers of the Ϫ308A variant. However, elucidation of the precise mechanisms underlying the relationship between the TNF␣ system and androgen excess is needed before considering TNF␣ as a significant contributing factor to the development of hyperandrogenism.
